New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
18:58 EDTOUTR, CTRL, SRPT, GPRO, ARRS, MHK, TSLA, SPWR, WWWW, DATA, PCLN, IMPV, EXPE, LNKDOn The Fly: After Hours Movers
UP AFTER EARNINGS: Imperva (IMPV), up 13.4% after reporting quarterly results... LinkedIn (LNKD), up 7.7% after reporting better than expected second quarter results and guidance for third quarter and fiscal 2014... Expedia (EXPE), up 2.1% after reporting second quarter results above analyst estimates and raising its quarterly dividend... Priceline (PCLN), up marginally following Expedia's second quarter results...Tableau Software (DATA), up 1.5%... Mohawk (MHK), up 3%. ALSO HIGHER: Sarepta Therapeutics (SRPT), up 3.4% after the FDA said that it will explore quick approval of DMD drugs. DOWN AFTER EARNINGS: Web.com (WWWW), down 16.8% after reporting second quarter results and acquiring UK online directory company Scoot... ARRIS Group (ARRS), down 8.6%... Control4 (CTRL), down 11.1%... SunPower (SPWR), down 5%... GoPro (GPRO), down 11.2%... Outerwall (OUTR), down 2%... Tesla (TSLA), down marginally after reporting second quarter results and announcing that it broke ground on a possible Gigafactory location in Reno, Nevada.
News For IMPV;LNKD;EXPE;PCLN;DATA;MHK;SRPT;WWWW;ARRS;CTRL;SPWR;GPRO;OUTR;TSLA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
August 21, 2015
10:36 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: PTCT UVXY VIX VXX SVXXY SRPT TZA UPRO VNR SPXU
09:34 EDTTSLAActive equity options trading on open
Active equity options trading on open: AAPL FB BAC NFLX DIS TSLA TWTR
08:32 EDTSRPTSarepta says FDA grants rare pediatric disease designation for Eteplirsen
Subscribe for More Information
06:56 EDTSPWRSolar companies spending $1B in Texas projects, WSJ says
Subscribe for More Information
August 20, 2015
12:56 EDTGPROSmall drones bringing air traffic problems in U.S., Washington Post reports
Subscribe for More Information
11:49 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: SRPT ACHN VIAV ZG RAD DIS ORCL SPY XLF OEX
10:22 EDTLNKDAfter meeting with CEO, JPMorgan says buy LinkedIn
After meeting with LinkedIn's CEO Jeff Weiner and CFO Steve Sordello, JPMorgan tells investors to buy the stock. Calling the recent decline in the shares a buying opportunity, the firm is upbeat about the outlook for the company's Talent, Marketing, and Sales Navigation units. WHAT'S NEW: Talent has performed well since the company assigned new sales professionals to most of its accounts in the first quarter, JPMorgan analyst Doug Anmuth quoted LinkedIn as saying. Additionally, the company improved Talent by enabling users to search by key criteria such as hiring volume and overall spending potential, Anmuth believes. Meanwhile, LinkedIn is improving Marketing by replacing display ads with sponsored updates which have higher click through rates and pricing, the analyst added. As a result of this change, Marketing's growth could reaccelerate in 2016, Anmuth contended. Additionally, LinkedIn's recently acquired online learning website, Lynda.com, is "just beginning to ramp," and its Sales Navigation unit is poised to make bigger deals with corporations, Anmuth believes. The analyst kept a $300 price target and Overweight rating on the shares. WHAT'S NOTABLE: On August 13, research firm Stifel called LinkedIn its "best emerging large cap idea." The firm expects positive catalysts to emerge for the company in the second half of 2015. It kept a Buy rating on the shares. PRICE ACTION: In early trading, LinkedIn lost 0.7% to $188.
06:57 EDTLNKDLinkedIn pullback a buying opportunity, says JPMorgan
JPMorgan analyst Doug Anmuth recommends using the recent pullback in shares of LinkedIn as a buying opportunity. After meeting with management, including CEO Jeff Weiner and CFO Steve Sordello, Anmuth reiterates an Overweight rating on the stock. Management's tone was upbeat as Talent metrics have improved, the analyst points out. He keeps a $300 price target on the name.
August 19, 2015
18:40 EDTTSLAAudi electric SUV entering production in 2018 with 310 mile range
Volkswagen's (VLKAY) Audi (AUDVF) released additional details on its forthcoming "e-tron Quattro" electric SUV. The company said "the latest battery technology" will provide a range of more than 310 miles, adding that the SUV will be "in series production from 2018." In an August 13 press release, the company said it will be partnering with LG Chem and Samsung (SSNLF) SDI on batteries for the vehicle. Note that on August 5, Tesla (TSLA) stated that its Model X crossover utility vehicle remains on track for a late Q3 launch. Reference Link
13:11 EDTSPWRCanadian Solar plummets after Q3 guidance, YieldCo comments
Subscribe for More Information
11:50 EDTTSLATesla mentioned cautiously by Seeking Alpha contributor
Subscribe for More Information
10:35 EDTMHKMohawk management to meet with SunTrust
Meetings to be held in New York August 26-27 hosted by SunTrust.
09:17 EDTSRPT'Female Viagra' approval seen as positive for Sarepta, BioMarin
The FDA's approval of the world's first drug designed to boost a woman's sexual desire is seen as boding well for companies awaiting critical decisions by the agency. FEMALE VIAGRA: The Food and Drug Administration yesterday approved flibanserin to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug, which will be sold under the name "Addyi" and is commonly referred to as the "female Viagra," is the first FDA-approved treatment for sexual desire disorders in men or women, the agency prominently stated in its press release. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance, the FDA explained. Addyi was approved with a risk evaluation and mitigation strategy as well as a Boxed Warning given the risk of severe hypotension and syncope in patients who drink alcohol during treatment. The drug is made by privately held Sprout Pharmaceuticals. ANALYST REACTION: Addyi's approval is "another sign of flexibility" by the FDA, especially for first-in-class therapies, Roth Capital analyst Debjit Chattopadhyay writes this morning in a note to investors. This bodes well for the approval of eteplirsen, drisapersen and Translarna, the analyst contends. Eteplirsen, designed by Sarepta Therapeutics (SRPT), and drisapersen, designed by BioMarin (BMRN), are experimental drugs being developed to treat Duchenne muscular dystrophy. Translarna, designed by PTC Therapeutics (PTCT), is already being sold in Europe as a treatment for DMD and is awaiting approval from the FDA. Duchenne muscular dystrophy is a form of muscular dystrophy affecting around 1 in 3,600 boys, which results in muscle degeneration and premature death. SAVING LIVES: While female sexual dysfunction is a clinical problem, eteplirsen is designed to save lives, Chattopadhyay points out. He has a Buy rating on Sarepta and noted his price target of $45 assumes accelerated approval for eteplirsen in the first quarter of 2016. Shares of the Massachusetts-based biopharmaceutical company closed yesterday at $35.69.
09:02 EDTDATATableau launches operations in China
Subscribe for More Information
08:29 EDTSRPTFlibanserin approval bodes well for Sarepta, others, says Roth Capital
Subscribe for More Information
07:54 EDTLNKDLinkedIn management to meet with Pacific Crest
Meeting to be held on the West Coast on August 25 hosted by Pacific Crest.
05:44 EDTWWWWWeb.com cyber breach appears limited, says JPMorgan
JPMorgan analyst Sterling Auty says Web.com's cyber security breach appears limited since only 3% of the customer base is impacted. Auty added to his model $200,000 of expenses to Web.com's September quarter and $100,000 to the December quarter. He keeps a Neutral rating on the name with a $25 price target.
05:40 EDTWWWWWeb.com breach to impact earnings by about 1%, says Piper Jaffray
Subscribe for More Information
August 18, 2015
16:50 EDTWWWWWeb.com discovered unauthorized breach on one of its systems
Subscribe for More Information
16:00 EDTTSLAOptions Update; August 18, 2015
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use